Molecure S.A.

WSE:MOC Stock Report

Market Cap: zł153.2m

Molecure Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Marcin Szumowski

Chief executive officer

zł473.2k

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.7%
Management average tenure4.1yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04
OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24
Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02
Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

CEO

Marcin Szumowski

no data

Tenure

zł473,205

Compensation

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...

Leadership Team

NamePositionTenureCompensationOwnership
Marcin Szumowski
Co-Founderno datazł473.21k0.70%
PLN 1.1m
Slawomir Broniarek
CFO & Member of the Management Boardno datazł421.09k0.20%
PLN 314.0k
Zbigniew Zaslona
Chief Scientific Officer & Member of Management Board3.1yrszł473.21k0.11%
PLN 171.9k
Agnieszka Rajczuk-Szczepanska
Member of Management Board & HR Director5.1yrszł348.41k0.034%
PLN 52.8k
Adam Golebiowski
Co-Founder & VP of Research Chemistry13.1yrszł500.00k3.01%
PLN 4.6m
Jacek Olczak
Co-Founder & Head of Medicinal Chemistryno datano datano data
Piotr Iwanowski
Chief Medical Officer & Member of Management Board1.1yrsno datano data
Magdalena Tyszkiewicz
Head of CMC5.1yrsno datano data
Marta Borkowska
Director of the Management Board Office3.1yrsno datano data

4.1yrs

Average Tenure

Experienced Management: MOC's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Luke O'Neill
Member of Scientific Advisory Boardno datano datano data
Bart Lambrecht
Member of Scientific Advisory Boardno datano datano data
Tomasz Piec
Vice Chairman of the Supervisory Board5.1yrszł133.62kno data
Douglas Hay
Member of Scientific Advisory Boardno datano datano data
Paul Van Der Horst
Independent Chairman of the Supervisory Board3.1yrszł132.99k0.059%
PLN 91.0k
Nancy Van Osselaer
Independent Member of the Supervisory Board3.1yrszł124.22kno data
Agnieszka Motyl
Member of the Supervisory Board1.6yrszł44.45kno data
Pawel Trawkowski
Independent Member of the Supervisory Board2.7yrszł124.22kno data

3.1yrs

Average Tenure

Experienced Board: MOC's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 12:41
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecure S.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Lukasz KosiarskiIpopema Securities S.A.